• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本胃肠道间质瘤患者的流行病学特征及管理中的年龄相关差异:一项国家癌症登记研究

Epidemiologic Features and Age-Related Differences in Management among Patients with Gastrointestinal Stromal Tumors in Japan: A National Cancer Registry Study.

作者信息

Hirano Hidekazu, Naito Yoichi, Nishida Toshirou, Higashi Takahiro, Satake Tomoyuki, Morizane Chigusa, Kawai Akira

机构信息

Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.

Department of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan.

出版信息

Cancer Res Commun. 2025 Jul 1;5(7):1235-1242. doi: 10.1158/2767-9764.CRC-25-0074.

DOI:10.1158/2767-9764.CRC-25-0074
PMID:40673479
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12304871/
Abstract

UNLABELLED

Data on the epidemiology of gastrointestinal stromal tumor (GIST) and differences in its management according to age group are limited in Japan. We aimed to conduct an epidemiologic evaluation and describe age-related differences in management using data from Japan's National Cancer Registry. We analyzed National Cancer Registry data of 21,426 patients with GIST between 2016 and 2019. We compared information on demographics, treatment, and prognosis across three age groups: pediatric and adolescent young adult (PAYA; ≤39 years), adult (40-74 years), and geriatric (≥75 years). Crude and age-adjusted annual incidences of GIST were 4.23 and 4.20 per 100,000 population, respectively. Regional variations in average age-adjusted annual incidence were observed among prefectures. The most common primary organs were stomach (72%), followed by the small intestine (21%). Geriatric patients represented 33% of the total population. Relative to PAYA and adult patients, geriatric patients were less likely to undergo surgery in the nonmetastatic setting (PAYA, 93%; adult, 93%; and geriatric, 87%; P < 0.001) or to receive chemotherapy in the metastatic setting (PAYA, 90%; adult, 87%; and geriatric, 61%; P < 0.001). Geriatric patients showed poorer 2-year overall survival relative to PAYA and adult patients in the nonmetastatic (PAYA, 98.5%; adult, 97.2%; and geriatric, 89.2%; P < 0.001) and metastatic (PAYA, 92.9%; adult, 79.2%; and geriatric, 54.7%; P < 0.001) settings. Geriatric patients comprised one third of the study population and were associated with less active treatment and an unfavorable prognosis.

SIGNIFICANCE

This is the first report presenting comprehensive Japanese epidemiologic data on GIST at a national level.

摘要

未标注

在日本,关于胃肠道间质瘤(GIST)的流行病学数据以及根据年龄组划分的治疗差异有限。我们旨在利用日本国家癌症登记处的数据进行流行病学评估,并描述治疗方面与年龄相关的差异。我们分析了2016年至2019年间21426例GIST患者的国家癌症登记数据。我们比较了三个年龄组的人口统计学、治疗和预后信息:儿童及青少年青年成人(PAYA;≤39岁)、成人(40 - 74岁)和老年(≥75岁)。GIST的粗年发病率和年龄调整年发病率分别为每10万人4.23例和4.20例。各都道府县观察到平均年龄调整年发病率的地区差异。最常见的原发器官是胃(72%),其次是小肠(21%)。老年患者占总人口的33%。与PAYA和成年患者相比,老年患者在非转移情况下接受手术的可能性较小(PAYA为93%;成年为93%;老年为87%;P < 0.001),在转移情况下接受化疗的可能性也较小(PAYA为90%;成年为87%;老年为61%;P < 0.001)。在非转移(PAYA为98.5%;成年为97.2%;老年为89.2%;P < 0.001)和转移(PAYA为92.9%;成年为79.2%;老年为54.7%;P < 0.001)情况下,老年患者的2年总生存率相对于PAYA和成年患者较差。老年患者占研究人群的三分之一,且与治疗积极性较低和预后不良相关。

意义

这是第一份在国家层面呈现日本关于GIST综合流行病学数据的报告。

相似文献

1
Epidemiologic Features and Age-Related Differences in Management among Patients with Gastrointestinal Stromal Tumors in Japan: A National Cancer Registry Study.日本胃肠道间质瘤患者的流行病学特征及管理中的年龄相关差异:一项国家癌症登记研究
Cancer Res Commun. 2025 Jul 1;5(7):1235-1242. doi: 10.1158/2767-9764.CRC-25-0074.
2
Gastrointestinal stromal tumors of the upper GI tract: population-based analysis of epidemiology, treatment and outcome based on data from the German Clinical Cancer Registry Group.上消化道胃肠间质瘤:基于德国临床癌症研究组数据的流行病学、治疗和预后的基于人群分析。
J Cancer Res Clin Oncol. 2023 Aug;149(10):7461-7469. doi: 10.1007/s00432-023-04690-6. Epub 2023 Mar 23.
3
What Are the Complications, Function, and Survival of Tumor-devitalized Autografts Used in Patients With Limb-sparing Surgery for Bone and Soft Tissue Tumors? A Japanese Musculoskeletal Oncology Group Multi-institutional Study.肿瘤灭活自体移植物用于保肢手术治疗骨和软组织肿瘤患者的并发症、功能和生存情况如何?日本肌肉骨骼肿瘤学组多机构研究。
Clin Orthop Relat Res. 2023 Nov 1;481(11):2110-2124. doi: 10.1097/CORR.0000000000002720. Epub 2023 Jun 14.
4
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
5
Prognostic Significance of Circulating Tumor DNA Mutations in Gastrointestinal Stromal Tumors: A Systematic Review and Meta-analysis Based on Time-To-Event Data.胃肠道间质瘤中循环肿瘤DNA突变的预后意义:基于事件发生时间数据的系统评价和荟萃分析
J Gastrointest Cancer. 2025 Jul 15;56(1):153. doi: 10.1007/s12029-025-01271-3.
6
Increasing Trends of Pediatric Thoracic and Lumbar Spine Fractures in the United States from 2004 to 2023: A 20-year National Injury Review Depicting Shifts in Mechanisms of Injury.2004年至2023年美国儿童胸腰椎骨折的增长趋势:一项为期20年的全国性损伤回顾,描绘损伤机制的变化
Clin Orthop Relat Res. 2025 Feb 25. doi: 10.1097/CORR.0000000000003421.
7
Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.伊马替尼治疗不可切除和/或转移性胃肠道间质瘤患者:系统评价与经济学评估
Health Technol Assess. 2005 Jul;9(25):1-142. doi: 10.3310/hta9250.
8
Are There Differences in Performance Among Femoral Stem Brands Utilized in Cementless Hemiarthroplasty for Treatment of Geriatric Femoral Neck Fractures?在用于治疗老年股骨颈骨折的非骨水泥半髋关节置换术中,不同品牌的股骨柄在性能上是否存在差异?
Clin Orthop Relat Res. 2025 Feb 1;483(2):253-264. doi: 10.1097/CORR.0000000000003222. Epub 2024 Aug 15.
9
Do Patients of Different Levels of Affluence Receive Different Care for Pediatric Osteosarcomas? One Institution's Experience.不同富裕程度的患者在小儿骨肉瘤治疗上是否得到不同的护理?一家机构的经验。
Clin Orthop Relat Res. 2025 Apr 1;483(4):748-758. doi: 10.1097/CORR.0000000000003299. Epub 2024 Oct 30.
10
Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.伊马替尼剂量升级治疗 400mg/天治疗进展的不可切除和/或转移性胃肠道间质瘤的临床疗效和成本效益:系统评价和经济评估。
Health Technol Assess. 2011 Jun;15(25):1-178. doi: 10.3310/hta15250.

本文引用的文献

1
Impact of cancer and other causes of death on mortality of cancer patients: A study based on Japanese population-based registry data.癌症和其他死因对癌症患者死亡率的影响:基于日本人群登记数据的研究。
Int J Cancer. 2023 Sep 15;153(6):1162-1171. doi: 10.1002/ijc.34610. Epub 2023 Jun 6.
2
Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan.在日本和中国台湾的老年患者中使用伊马替尼治疗胃肠道间质瘤。
Sci Rep. 2022 Dec 28;12(1):22492. doi: 10.1038/s41598-022-27092-z.
3
Overview of the ethical guidelines for medical and biological research involving human subjects in Japan.
日本涉及人体医学和生物学研究的伦理准则概述。
Jpn J Clin Oncol. 2022 May 31;52(6):539-544. doi: 10.1093/jjco/hyac034.
4
Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.胃肠道间质瘤:ESMO-EURACAN-GENTURIS诊断、治疗及随访临床实践指南
Ann Oncol. 2022 Jan;33(1):20-33. doi: 10.1016/j.annonc.2021.09.005. Epub 2021 Sep 21.
5
Gastrointestinal stromal tumours.胃肠道间质瘤。
Nat Rev Dis Primers. 2021 Mar 18;7(1):22. doi: 10.1038/s41572-021-00254-5.
6
Primary Tumor Resection Improves Survival in Patients With Metastatic Gastrointestinal Stromal Tumors: A Preliminary Population-Based Analysis.原发性肿瘤切除可提高转移性胃肠道间质瘤患者的生存率:一项基于人群的初步分析。
Front Oncol. 2020 Aug 19;10:1440. doi: 10.3389/fonc.2020.01440. eCollection 2020.
7
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.与辅助伊马替尼治疗 1 年相比,3 年治疗高危胃肠道间质瘤患者的生存结局:10 年随访后一项随机临床试验的分析。
JAMA Oncol. 2020 Aug 1;6(8):1241-1246. doi: 10.1001/jamaoncol.2020.2091.
8
Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology.老年化疗患者脆弱性的实用评估和管理:ASCO 老年肿瘤学指南。
J Clin Oncol. 2018 Aug 1;36(22):2326-2347. doi: 10.1200/JCO.2018.78.8687. Epub 2018 May 21.
9
Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).老年晚期胃肠道间质瘤(GIST)患者的治疗结局。
J Geriatr Oncol. 2018 Sep;9(5):520-525. doi: 10.1016/j.jgo.2018.03.009. Epub 2018 Mar 27.
10
Elderly patients with gastrointestinal stromal tumour (GIST) receive less treatment irrespective of performance score or comorbidity - A retrospective multicentre study in a large cohort of GIST patients.老年胃肠道间质瘤(GIST)患者无论其体能状态评分或合并症如何,接受的治疗都较少——一项对大量GIST患者队列的回顾性多中心研究。
Eur J Cancer. 2017 Nov;86:318-325. doi: 10.1016/j.ejca.2017.09.017. Epub 2017 Oct 23.